{"success":true,"data":{"pressRelease":{"id":"164081","rtpr_id":"nPrepbV5Da-20261008","ticker":"SOBIV","exchange":"Nasdaq Stockholm","all_tickers":["SOBIV"],"title":"Invitation: Sobi's Q3 2026 report","author":"PR Newswire","published_at":"2026-10-08T11:20:39.787Z","article_body":"Invitation: Sobi's Q3 2026 report\nPR Newswire\n\nSTOCKHOLM, Oct. 8, 2026\n\nSobi plans to publish its report for the third quarter of 2026 on 27 October\n2026 at 08:00 CET.\n\nSTOCKHOLM, Oct. 8, 2026 /PRNewswire/ -- Investors, analysts, and the media\nare invited to a conference call on the same day at 15:00 CET, 14:00 GMT, and\n10:00 EDT. The call will include a presentation of the results and a Q&A\nsession.\n\nThe presentation can be followed live here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=88918930&u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3D2CyupiYg&a=here) or\nafterwards on sobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com).\nThe slides will be made available on sobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com)\nbefore the conference call.\n\nTo participate in the conference call, please use the following dial-in\ndetails:\n\nHD Web Phone™: click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=1205581621&u=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fhdswiss.choruscall.com%252F%253Fcalltype%253D2%2526h%253Dtrue%2526r%253Dtrue%2526info%253Dcompany%26data%3D05%257C02%257CJennifer.Kretzmann%2540sobi.com%257C1cac7dcaced64193aad408df07389275%257C2a2b3b7c21024caf911ef24595387c50%257C0%257C0%257C639237611739354168%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DSNloYwlWTOm9nCszZ7kKNtM4mAuksfrIWATe1VLQ16E%253D%26reserved%3D0&a=click+here)\nSweden: +46 8 5051 0031\nUnited Kingdom: +44 203 059 58 63\nUnited States: +1 631 570 56 13\n\nFor other countries, please find the details here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=1596853810&u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fservices3.choruscall.ch%252FNUMBERS%252FAttended_Dial_In_Numbers.pdf%26data%3D05%257C02%257Cssantamaria%2540choruscall.com%257Cc46caccf82394f1c8ffd08dc369c2a22%257Cb33d8fee5ac94ed69e4d5ad041ecfd21%257C0%257C0%257C638445292073810488%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C0%257C%257C%257C%26sdata%3DTVLldmPZmSnOWKSwGGe2CdG1TlgV7dEF2ypcHkkECNE%253D%26reserved%3D0&a=here).\n\nSobi®\n\nSobi is a global biopharma company unlocking the potential of breakthrough\ninnovations, transforming everyday life for people living with rare diseases.\nSobi has approximately 2,000 employees across Europe, North America, the\nMiddle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion.\nSobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at\nsobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com) and\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=261530320&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsobi%2F&a=LinkedIn).\n\nContacts\n\nFor details on how to contact the Sobi Investor Relations Team, please click\nhere\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=3989184891&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fir-contacts&a=here).\nFor Sobi Media contacts, click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=3193475396&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fmedia&a=here).\n\nGerard Tobin\nHead of Investor Relations\n\nThis information was brought to you by Cision http://news.cision.com.\n\nhttps://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q3-2026-report,c4394963\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/14266/4394963/4264943.pdf  Invitation Sobi's Q3 2026 report  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q3-2026-report-302902391.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPrepbV5Da-20261008","title":"Invitation: Sobi's Q3 2026 report","author":"PR Newswire","ticker":"SOBIV","created":"2026-10-08T11:20:39.787Z","tickers":["SOBIV"],"exchange":"Nasdaq Stockholm","article_body":"Invitation: Sobi's Q3 2026 report\nPR Newswire\n\nSTOCKHOLM, Oct. 8, 2026\n\nSobi plans to publish its report for the third quarter of 2026 on 27 October\n2026 at 08:00 CET.\n\nSTOCKHOLM, Oct. 8, 2026 /PRNewswire/ -- Investors, analysts, and the media\nare invited to a conference call on the same day at 15:00 CET, 14:00 GMT, and\n10:00 EDT. The call will include a presentation of the results and a Q&A\nsession.\n\nThe presentation can be followed live here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=88918930&u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3D2CyupiYg&a=here) or\nafterwards on sobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com).\nThe slides will be made available on sobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com)\nbefore the conference call.\n\nTo participate in the conference call, please use the following dial-in\ndetails:\n\nHD Web Phone™: click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=1205581621&u=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fhdswiss.choruscall.com%252F%253Fcalltype%253D2%2526h%253Dtrue%2526r%253Dtrue%2526info%253Dcompany%26data%3D05%257C02%257CJennifer.Kretzmann%2540sobi.com%257C1cac7dcaced64193aad408df07389275%257C2a2b3b7c21024caf911ef24595387c50%257C0%257C0%257C639237611739354168%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DSNloYwlWTOm9nCszZ7kKNtM4mAuksfrIWATe1VLQ16E%253D%26reserved%3D0&a=click+here)\nSweden: +46 8 5051 0031\nUnited Kingdom: +44 203 059 58 63\nUnited States: +1 631 570 56 13\n\nFor other countries, please find the details here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=1596853810&u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fservices3.choruscall.ch%252FNUMBERS%252FAttended_Dial_In_Numbers.pdf%26data%3D05%257C02%257Cssantamaria%2540choruscall.com%257Cc46caccf82394f1c8ffd08dc369c2a22%257Cb33d8fee5ac94ed69e4d5ad041ecfd21%257C0%257C0%257C638445292073810488%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C0%257C%257C%257C%26sdata%3DTVLldmPZmSnOWKSwGGe2CdG1TlgV7dEF2ypcHkkECNE%253D%26reserved%3D0&a=here).\n\nSobi®\n\nSobi is a global biopharma company unlocking the potential of breakthrough\ninnovations, transforming everyday life for people living with rare diseases.\nSobi has approximately 2,000 employees across Europe, North America, the\nMiddle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion.\nSobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at\nsobi.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=432096735&u=https%3A%2F%2Fwww.sobi.com%2Fen&a=sobi.com) and\nLinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=261530320&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsobi%2F&a=LinkedIn).\n\nContacts\n\nFor details on how to contact the Sobi Investor Relations Team, please click\nhere\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=3989184891&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fir-contacts&a=here).\nFor Sobi Media contacts, click here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792670-1&h=3193475396&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fmedia&a=here).\n\nGerard Tobin\nHead of Investor Relations\n\nThis information was brought to you by Cision http://news.cision.com.\n\nhttps://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q3-2026-report,c4394963\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/14266/4394963/4264943.pdf  Invitation Sobi's Q3 2026 report  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q3-2026-report-302902391.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T11:20:39.827421054Z","server_sent_at_ms":1791458439827},"received_at":"2026-10-08T11:20:39.884Z","source_url":null},"analysis":{"id":"152517","press_release_id":"164081","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Sobi will publish its Q3 2026 report on 27 October 2026 at 08:00 CET.\n\nInvestors, analysts, and media are invited to a conference call the same day at 15:00 CET, 14:00 GMT, and 10:00 EDT, with a presentation and Q&A.\n\nSobi is a global rare-disease biopharma company with roughly 2,000 employees and 2025 revenue of SEK 28 billion; its shares trade on Nasdaq Stockholm.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar note: Sobi Q3 2026 earnings due 27 October with conference call at 15:00 CET."},"keyFigures":{"customDimensions":{"employees":"approximately 2,000","report_date":"27 October 2026 at 08:00 CET","revenue_2025":"SEK 28 billion","conference_call_time":"15:00 CET, 14:00 GMT, 10:00 EDT"}},"quotedText":"","namedEntities":{"people":[{"name":"Gerard Tobin","role":"Head of Investor Relations"}],"products":[],"companies":[{"name":"Sobi","ticker":"SOBIV"}],"dollarAmounts":[{"amount":"SEK 28 billion","context":"Sobi 2025 revenue"}]},"materialImpact":{"score":1,"reasoning":"This is a routine earnings-date/conference-call invitation with no results or guidance. Boilerplate scheduling notice only."},"tickerRelevance":{"others":[],"primary":"SOBIV"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"international mid-cap","eventGravity":"earnings-date-scheduling-notice","householdBrandBoost":false,"retailFavoriteBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Sobi will publish its Q3 2026 report on 27 October 2026 at 08:00 CET.\n\nInvestors, analysts, and media are invited to a conference call the same day at 15:00 CET, 14:00 GMT, and 10:00 EDT, with a presentation and Q&A.\n\nSobi is a global rare-disease biopharma company with roughly 2,000 employees and 2025 revenue of SEK 28 billion; its shares trade on Nasdaq Stockholm.","key_figures":{"customDimensions":{"employees":"approximately 2,000","report_date":"27 October 2026 at 08:00 CET","revenue_2025":"SEK 28 billion","conference_call_time":"15:00 CET, 14:00 GMT, 10:00 EDT"}},"named_entities":{"people":[{"name":"Gerard Tobin","role":"Head of Investor Relations"}],"products":[],"companies":[{"name":"Sobi","ticker":"SOBIV"}],"dollarAmounts":[{"amount":"SEK 28 billion","context":"Sobi 2025 revenue"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:20:44.245Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"international mid-cap","eventGravity":"earnings-date-scheduling-notice","householdBrandBoost":false,"retailFavoriteBoost":false}},"durationMs":4425,"modelName":"glm-5.3-flashx"}}